- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.03. | Amgen's Uplizna shows promise in phase 3 generalised myasthenia gravis study | ||
| 17.03. | 2025 PM Society Awards - winners announced | ||
| 14.03. | AstraZeneca/Ionis' Wainzua granted EC approval to treat rare disease ATTRv-PN | ||
| 14.03. | DSRU appoints Linda Härmark as director | ||
| 14.03. | Prime minister unveils UK government's plans to abolish NHS England | ||
| 13.03. | World Kidney Day - Boehringer launches CKD initiative to tackle UK health inequalities | ||
| 13.03. | Biogen initiates phase 3 study of felzartamab in kidney transplant patients | ||
| 13.03. | NICE recommends Gideon Richter's Ryeqo as first daily pill for endometriosis | ||
| 12.03. | Roche and Zealand Pharma partner on mid-stage obesity candidate in deal worth $5.3bn | ||
| 12.03. | Merck KGaA's Mavenclad tablets recommended by NICE for wider MS use | ||
| 12.03. | Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis | ||
| 11.03. | Novartis gains rights to Kyorin's chronic spontaneous urticaria candidate in deal worth $830m | ||
| 11.03. | Vertex's triple combination cystic fibrosis therapy Alyftrek approved by MHRA | ||
| 11.03. | J&J/Protagonist's icotrokinra shows promise in phase 3 plaque psoriasis programme | ||
| 10.03. | Organon shares positive long-term results for Vtama cream in atopic dermatitis | ||
| 10.03. | FDA approves Celltrion's denosumab biosimilars Stoboclo and Osenvelt | ||
| 10.03. | Preparing biotechs for spin-out and beyond | ||
| 10.03. | BMS granted EC approval for immunotherapy combination in liver cancer | ||
| 07.03. | J&J's Lazcluze/Rybrevant combination granted MHRA approval for lung cancer | ||
| 07.03. | AstraZeneca announces promising late-stage results for Imfinzi in gastric cancer | ||
| 07.03. | Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer | ||
| 07.03. | What is it all for? | ||
| 06.03. | Novo Nordisk and Gensaic enter cardiometabolic disease partnership worth $354m | ||
| 06.03. | Eli Lilly's Jaypirca recommended by CHMP to treat chronic lymphocytic leukaemia | ||
| 06.03. | Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
